Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Upstream Biosciences has reported that the company's novel drug candidates to treat the parasitic disease leishmaniasis have demonstrated good safety profiles in their first in vivo toxicity tests in mice.
Subscribe to our email newsletter
The toxicity screening studies were conducted at Makerere University in Uganda, which is also conducting initial efficacy and toxicity screening for Upstream’s candidates to treat trypanosomiasis, or African sleeping sickness. The Makerere researchers reported that the leishmaniasis candidates were well tolerated by mice at doses that were many times higher than the expected therapeutic dose levels, up to 25 mg/kg, with no signs of serious toxicity.
Joel Bellenson, CEO of Upstream, said: “These positive toxicity results in mammals represent a major milestone for our program to develop new agents to treat tropical parasitic diseases. The excellent safety profile seen to date with our novel structural class is another validation of our artificial intelligence approach to drug discovery.”